White label ELPA - ClinicalTrials.eu

Study Comparing BMS-986393 CAR T Cell Therapy to Standard Treatments for Adults with Relapsed or Refractory Multiple Myeloma Resistant to Lenalidomide

Recruiting

3 1 1 1
Investigated diseases:
- Plasma cell myeloma refractory
+11
Study on Dapagliflozin, Finerenone, and Semaglutide for Treating Chronic Kidney Disease in Patients

Recruiting

3 1 1 1
Investigated diseases:
- Chronic kidney disease
Study on Preoperative Antibiotics for Patients with Acute Cholecystitis: Comparing Ertapenem, Ciprofloxacin, and Cefuroxime

Recruiting

3 1 1 1
Investigated diseases:
- Cholecystitis acute
Study on the Safety and Effects of BMS-986507 with Pembrolizumab and Osimertinib Mesylate in Adults with Advanced Solid Tumors

Recruiting

1 1 1 1
Investigated diseases:
- Neoplasm malignant
Study of pacritinib effectiveness and safety compared to placebo in patients with VEXAS syndrome

Recruiting

2 1
Investigated diseases:
- VEXAS syndrome
Study Comparing Duvelisib with Gemcitabine or Bendamustine for Patients with Relapsed or Resistant T Cell Lymphoma Originating from T Follicular Helper Cells

Recruiting

3 1 1 1

+3
Title: Evaluation of lorazepam, pregabalin, and olanzapine in treating agitated behavior in dementia patients who did not respond to standard treatments

Recruiting

3 1 1
Investigated diseases:
- Dementia
Study on Encorafenib, Binimetinib, Cemiplimab, and Fianlimab for Patients with BRAF-Mutated Melanoma and Brain Metastases

Recruiting

2 1 1 1
Investigated diseases:
- Malignant melanoma
Study on MB-CART2219.1 for Adults and Children with Relapsed or Refractory B-cell Malignancies

Recruiting

1 1 1
Investigated diseases:
- Acute lymphocytic leukaemia
Study of ABBV-400 and Budigalimab for Adults with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Recruiting

1 1 1 1
Investigated diseases:
+1

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies